Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Loh

Showing results (311-320 of 479) with videos related to

Pageof 48
Sort By:
Future Oncology (London, England)|March 30, 2018
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignanciesAndrew E Place, Kelly Goldsmith, Jean-Pierre Bourquin, et al.
JCI Insight|July 27, 2018
Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomesJasmine C Wong, Victoria Bryant, Tamara Lamprecht, et al.
Leukemia|April 13, 2021
Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Cell Genomics|December 3, 2025
Analysis of error profiles of indels and structural variants in deep-sequencing dataYing Shao, Quang Tran, Yuan Feng, et al.
Haematologica|December 15, 2018
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COGMichael J Burke, Wanda L Salzer, Meenakshi Devidas, et al.
Haematologica|February 17, 2022
Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trialErin M Guest, John A Kairalla, Joanne M Hilden, et al.
Pediatric Blood & Cancer|February 9, 2021
Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology GroupRachel E Rau, Yunfeng Dai, Meenakshi Devidas, et al.
Leukemia|March 8, 2019
Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaDeepa Bhojwani, Richard Sposto, Nirali N Shah, et al.
Pediatric Blood & Cancer|August 17, 2023
Assessment of proxy-reported responses as predictors of motor and sensory peripheral neuropathy in children with B-lymphoblastic leukemiaRozalyn L Rodwin, Natalie J DelRocco, Emily Hibbitts, et al.
Leukemia|September 30, 2018
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaDeepa Bhojwani, Richard Sposto, Nirali N Shah, et al.
Pageof 48

Showing results (311-320 of 479) with videos related to

Sort By:
Pageof 48
Future Oncology (London, England)|March 30, 2018
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignanciesAndrew E Place, Kelly Goldsmith, Jean-Pierre Bourquin, et al.
JCI Insight|July 27, 2018
Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomesJasmine C Wong, Victoria Bryant, Tamara Lamprecht, et al.
Leukemia|April 13, 2021
Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Cell Genomics|December 3, 2025
Analysis of error profiles of indels and structural variants in deep-sequencing dataYing Shao, Quang Tran, Yuan Feng, et al.
Haematologica|December 15, 2018
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COGMichael J Burke, Wanda L Salzer, Meenakshi Devidas, et al.
Haematologica|February 17, 2022
Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trialErin M Guest, John A Kairalla, Joanne M Hilden, et al.
Pediatric Blood & Cancer|February 9, 2021
Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology GroupRachel E Rau, Yunfeng Dai, Meenakshi Devidas, et al.
Leukemia|March 8, 2019
Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaDeepa Bhojwani, Richard Sposto, Nirali N Shah, et al.
Pediatric Blood & Cancer|August 17, 2023
Assessment of proxy-reported responses as predictors of motor and sensory peripheral neuropathy in children with B-lymphoblastic leukemiaRozalyn L Rodwin, Natalie J DelRocco, Emily Hibbitts, et al.
Leukemia|September 30, 2018
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaDeepa Bhojwani, Richard Sposto, Nirali N Shah, et al.
Pageof 48